The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Thromboembolism


Psychiatry related information on Thromboembolism


High impact information on Thromboembolism


Chemical compound and disease context of Thromboembolism

  • Tamoxifen and thromboembolism [13].
  • Thus, cPLA(2)alpha plays a discrete role in the collagen-stimulated production of TX and its inhibition has a therapeutic potential against thromboembolism, with potentially limited bleeding expected [14].
  • Although FXII-deficient mice do not experience spontaneous or excessive injury-related bleeding, they are protected against collagen- and epinephrine-induced thromboembolism [15].
  • To resolve questions of drug actions, efficacy, and interactions for platelet-modifying agents used clinically, we have compared the relative capacities and mechanisms of aspirin, dipyridamole, sulfinpyrazone, and dazoxiben to prevent arterial thromboembolism in a baboon model [16].
  • BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens [17].

Biological context of Thromboembolism


Anatomical context of Thromboembolism


Gene context of Thromboembolism


Analytical, diagnostic and therapeutic context of Thromboembolism


  1. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. Hull, R., Delmore, T., Carter, C., Hirsh, J., Genton, E., Gent, M., Turpie, G., McLaughlin, D. N. Engl. J. Med. (1982) [Pubmed]
  2. Thrombocytopenia found uncommonly during heparin therapy. Powers, P.J., Cuthbert, D., Hirsh, J. JAMA (1979) [Pubmed]
  3. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Hulley, S., Furberg, C., Barrett-Connor, E., Cauley, J., Grady, D., Haskell, W., Knopp, R., Lowery, M., Satterfield, S., Schrott, H., Vittinghoff, E., Hunninghake, D. JAMA (2002) [Pubmed]
  4. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. Slungaard, A., Vercellotti, G.M., Tran, T., Gleich, G.J., Key, N.S. J. Clin. Invest. (1993) [Pubmed]
  5. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Hommes, D.W., Bura, A., Mazzolai, L., Büller, H.R., ten Cate, J.W. Ann. Intern. Med. (1992) [Pubmed]
  6. Trends in mortality rates comparing underlying-cause and multiple-cause coding in an English population 1979-1998. Goldacre, M.J., Duncan, M.E., Cook-Mozaffari, P., Griffith, M. Journal of public health medicine. (2003) [Pubmed]
  7. Endocrinologic treatment of gender identity disorders. Tangpricha, V., Ducharme, S.H., Barber, T.W., Chipkin, S.R. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. (2003) [Pubmed]
  8. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. Eriksson, B.I., Bauer, K.A., Lassen, M.R., Turpie, A.G. N. Engl. J. Med. (2001) [Pubmed]
  9. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. Schulman, S., Lindmarker, P. N. Engl. J. Med. (2000) [Pubmed]
  10. The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). Simioni, P., Prandoni, P., Lensing, A.W., Scudeller, A., Sardella, C., Prins, M.H., Villalta, S., Dazzi, F., Girolami, A. N. Engl. J. Med. (1997) [Pubmed]
  11. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. Comp, P.C., Esmon, C.T. N. Engl. J. Med. (1984) [Pubmed]
  12. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Fabre, J.E., Nguyen, M., Latour, A., Keifer, J.A., Audoly, L.P., Coffman, T.M., Koller, B.H. Nat. Med. (1999) [Pubmed]
  13. Tamoxifen and thromboembolism. Hendrick, A., Subramanian, V.P. JAMA (1980) [Pubmed]
  14. Discrete role for cytosolic phospholipase A(2)alpha in platelets: studies using single and double mutant mice of cytosolic and group IIA secretory phospholipase A(2). Wong, D.A., Kita, Y., Uozumi, N., Shimizu, T. J. Exp. Med. (2002) [Pubmed]
  15. Defective thrombus formation in mice lacking coagulation factor XII. Renné, T., Pozgajová, M., Grüner, S., Schuh, K., Pauer, H.U., Burfeind, P., Gailani, D., Nieswandt, B. J. Exp. Med. (2005) [Pubmed]
  16. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. Hanson, S.R., Harker, L.A., Bjornsson, T.D. J. Clin. Invest. (1985) [Pubmed]
  17. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Farmer, R.D., Lawrenson, R.A., Thompson, C.R., Kennedy, J.G., Hambleton, I.R. Lancet (1997) [Pubmed]
  18. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. Agnelli, G., Piovella, F., Buoncristiani, P., Severi, P., Pini, M., D'Angelo, A., Beltrametti, C., Damiani, M., Andrioli, G.C., Pugliese, R., Iorio, A., Brambilla, G. N. Engl. J. Med. (1998) [Pubmed]
  19. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Quéré, I., Perneger, T.V., Zittoun, J., Bellet, H., Gris, J.C., Daurès, J.P., Schved, J.F., Mercier, E., Laroche, J.P., Dauzat, M., Bounameaux, H., Janbon, C., de Moerloose, P. Lancet (2002) [Pubmed]
  20. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Yang, J., Wu, J., Kowalska, M.A., Dalvi, A., Prevost, N., O'Brien, P.J., Manning, D., Poncz, M., Lucki, I., Blendy, J.A., Brass, L.F. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  21. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Anand, S., Ginsberg, J.S., Kearon, C., Gent, M., Hirsh, J. Arch. Intern. Med. (1996) [Pubmed]
  22. Combined use of warfarin and adjusted subcutaneous heparin during pregnancy in patients with an artificial heart valve. Lee, P.K., Wang, R.Y., Chow, J.S., Cheung, K.L., Wong, V.C., Chan, T.K. J. Am. Coll. Cardiol. (1986) [Pubmed]
  23. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost? Eckman, M.H., Beshansky, J.R., Durand-Zaleski, I., Levine, H.J., Pauker, S.G. JAMA (1990) [Pubmed]
  24. Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. Green, D., Lee, M.Y., Lim, A.C., Chmiel, J.S., Vetter, M., Pang, T., Chen, D., Fenton, L., Yarkony, G.M., Meyer, P.R. Ann. Intern. Med. (1990) [Pubmed]
  25. Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. Blair, K.L., Hatton, A.C., White, W.D., Smith, L.R., Lowe, J.E., Wolfe, W.G., Young, W.G., Oldham, H.N., Douglas, J.M., Glower, D.D. Circulation (1994) [Pubmed]
  26. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Tsai, A.W., Cushman, M., Rosamond, W.D., Heckbert, S.R., Tracy, R.P., Aleksic, N., Folsom, A.R. Am. J. Med. (2002) [Pubmed]
  27. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. Butte, A.N., Houng, A.K., Jang, I.K., Reed, G.L. Circulation (1997) [Pubmed]
  28. Resistance to thromboembolism in PI3Kgamma-deficient mice. Hirsch, E., Bosco, O., Tropel, P., Laffargue, M., Calvez, R., Altruda, F., Wymann, M., Montrucchio, G. FASEB J. (2001) [Pubmed]
  29. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Bucciarelli, P., Rosendaal, F.R., Tripodi, A., Mannucci, P.M., De Stefano, V., Palareti, G., Finazzi, G., Baudo, F., Quintavalla, R. Arterioscler. Thromb. Vasc. Biol. (1999) [Pubmed]
  30. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Schambeck, C.M., Grossmann, R., Zonnur, S., Berger, M., Teuchert, K., Spahn, A., Walter, U. Thromb. Haemost. (2004) [Pubmed]
  31. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Hoke, M., Kyrle, P.A., Minar, E., Bialonzcyk, C., Hirschl, M., Schneider, B., Kollars, M., Weltermann, A., Eichinger, S. Thromb. Haemost. (2005) [Pubmed]
  32. Enoxaparin as prophylaxis against thromboembolism after total hip replacement. Pedell, L. N. Engl. J. Med. (1997) [Pubmed]
  33. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Leclerc, J.R., Geerts, W.H., Desjardins, L., Laflamme, G.H., L'Espérance, B., Demers, C., Kassis, J., Cruickshank, M., Whitman, L., Delorme, F. Ann. Intern. Med. (1996) [Pubmed]
  34. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Price, D.T., Ridker, P.M. Ann. Intern. Med. (1997) [Pubmed]
  35. Recurrence of venous thromboembolism after treatment with unfractionated heparin. Sutton, S.K. Ann. Intern. Med. (1996) [Pubmed]
  36. Increased platelet sensitivity to ADP in mice lacking platelet-type 12-lipoxygenase. Johnson, E.N., Brass, L.F., Funk, C.D. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
WikiGenes - Universities